Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395004 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 5
- Study locations
NCT01395004: Completed Phase 2 study of Langerhans Cell Histiocytosis, sponsored by GlaxoSmithKline.
NCT01395004 is a Phase 2 study of Langerhans Cell Histiocytosis that has completed, run by GlaxoSmithKline. The registered enrollment target is 17 participants, below the 1,137-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01395004, a Phase 2 study of Langerhans Cell Histiocytosis, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study was to assess safety and efficacy at months 3 and 6 in patients with Langerhans Cell Histiocytosis given daily oral doses of GSK2110183.
Conditions Studied
Interventions
- DRUG GSK2110183
Study Locations (5)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Staten Island University Hospital - Staten Island
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT01395004 record still lists
NCT01395004 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 1,137-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 1 intervention - of which GSK2110183 is the first listed.
NCT01395004 lists 5 locations in 4 states (New York, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT01395004 about?
NCT01395004 is a clinical study titled "A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis". The purpose of this study was to assess safety and efficacy at months 3 and 6 in patients with Langerhans Cell Histiocytosis given daily oral doses of GSK2110183.
What is the current status of trial NCT01395004?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2011-11. Estimated completion is 2013-11.
What conditions does trial NCT01395004 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT01395004?
The interventions under investigation include: GSK2110183 (DRUG).
Who is sponsoring clinical trial NCT01395004?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01395004 being conducted?
This trial has 5 study locations across Maryland, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01395004's enrollment target sits among peer trials
17 8th of 8 higher than 1 of 8 other Langerhans Cell Histiocytosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Langerhans Cell Histiocytosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
-
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia